Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease222

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease44

Views

Views
October 20250
November 20259
December 20258
January 202613
February 20260
March 202610
April 20264
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States22
Brazil5
France2
Kenya2
Argentina2
Côte d'Ivoire1
Germany1
Ecuador1
Egypt1
United Kingdom1
 

Top cities views

Views
San Jose11
Ashburn7
Nairobi2
Abidjan1
Al Mansurah1
Blumenau1
Conesa1
Contagem1
Ecatepec1
El Talar1